At Prana Thoracic, we’ve always been dedicated to innovation that transforms lives, starting with our advancements in precision surgery for lung cancer. Today, we’re excited to share a pivotal step in our journey: Prana Thoracic is becoming Prana Surgical. (1/4)
a wider range of medical needs. Thank you to our partners, investors, and advisors for your continued support as we embark on this next phase. Together, we’re shaping a future where precision surgical solutions bring life-saving potential to more patients. (3/4)
We plan to revolutionize the early diagnosis and treatment of #lungcancer by making it easier & less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity"
— #PranaThoracic Founders 🫁 (4/4)
"The paradigm of screening, detection, and early intervention that has been deployed in other major cancers (e.g. breast, colon) has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. (1/4)
Prana Thoracic aims to broaden treatment options for early-stage non-small cell lung cancer patients by excising nodules and providing direct access to the site.
Get the latest updates on Prana Thoracic here: https://t.co/1ZhwRlfPDR (3/3)
Small cell lung cancer (SCLC) is aggressive, grows rapidly, and often spreads early, leading to a challenging prognosis. Non-small cell lung cancer (NSCLC) is more common and grows at a slower rate, with a wider range of treatment options, including surgery for early stages.(1/3)
SCLC tends to metastasize quickly, while NSCLC often spreads initially to nearby lymph nodes. Advances in personalized treatments have improved outcomes for both types, underscoring the importance of early detection and tailored therapies. (2/3)
Our mission is to provide patients with definitive answers earlier in the progression of their disease when there is a higher likelihood of successful treatment.
Learn more about the ThoraCore™ here: https://t.co/TQqeAlxfyr
#PranaThoracic#ThoraCore#LungCancer (3/3)
Lung cancer often demands aggressive interventions that come with their own set of challenges. Traditional treatments, such as surgery and chemotherapy, can be invasive and carry significant risks. (1/3)
Prana Thoracic's ThoraCore™ technology aims to minimize the effect of excision on a patient’s lung function and quality of life while avoiding unnecessary surgery. (2/3)
Learn more about how Prana Thoracic is making strides toward the groundbreaking approach of precision lung cancer surgery and what that means for the future of this disease: https://t.co/BZ3VlWH1zM
#PranaThoracic#LungCancer#LungCancerSurgery#MedTech#MedDevice
The ThoraCore™️ is an electrosurgical instrument intended for cylindrical, single-port excision of targeted lung tissue, using bipolar RF energy for sealing. Here's how it works ⬇️
Only 26% of lung cancer cases are diagnosed at an early stage when the five-year survival rate is 61%. Unfortunately, 44% of cases are not caught until a late stage when the survival rate is only 7%. Getting screening before the appearance of symptoms can save your life.
Prana Thoracic is a Houston-based medical device startup dedicated to building solutions for early intervention in lung cancer. We are an experienced team of engineers, entrepreneurs, and surgeons focused on our mission to tackle the #1 cancer killer in the US.